AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7951008 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0
Study 7951008 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3300121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (two-dose peroperative regimen)
Number of subjects: 418
Study 3300121 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin and metronidazole (combined peroperative and postoperative for 4 days)
Number of subjects: 418
Study 30120478 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination pill (20 mg telmisartan, 2.5 mg amlodipine, 12.5 mg chlorthalidone)
Number of subjects: 700
Study 30120478 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study 30120478 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination pill
Number of subjects: 700
Study 29231403 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture based on meridian differentiation, with main acupoints including Neiguan (PC 6), Shuigou (GV 26), Sanyinjiao (SP 6), Fengchi (GB 20), Lianquan (CV 23), Jialianquan (Extra), Jinjin (EX-HN 12), Yuye (EX-HN 13), retained for 30 min, once daily, 5 treatments a week for 6 weeks.
Number of subjects: 130
Study 29231403 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication and rehabilitation training with control acupuncture points selected 5 cm lateral to the main acupoints, retained for 30 min, once daily, 5 treatments a week for 6 weeks.
Number of subjects: 130
Study 24286245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring microintervention (90 minutes)
Number of subjects: 92
Study 24286245 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (details not specified)
Number of subjects: 92
Study 24286245 — intervention group
Group type: COMPARATOR
Intervention: No-intervention condition
Number of subjects: 92
Study 23414648 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 3838
Study 23414648 — intervention group
Group type: COMPARATOR
Intervention: BE
Number of subjects: 3838
Study 20096399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive avoidance
Number of subjects: 1220
Study 20096399 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of emotion
Number of subjects: 1220
Study 20096399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive avoidance and GAD symptoms
Number of subjects: 1220
Study 18202581 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (moderate/vigorous-intensity aerobic activity for 60 min.d(‐1), 6 d.wk(‐1))
Number of subjects: 102
Study 18202581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in activity)
Number of subjects: 102
Study 16724119 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapotherm
Number of subjects: 30
Study 16724119 — intervention group
Group type: COMPARATOR
Intervention: High-flow
Number of subjects: 30
Study 14579049 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with non-fatal reinfarction
Number of subjects: 2109
Study 14579049 — intervention group
Group type: COMPARATOR
Intervention: Patients without non-fatal reinfarction
Number of subjects: 2109
Study 10943584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloricromene (100 mg orally b.i.d.) for 6 months
Number of subjects: 159
Study 10943584 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 159
Study 8606715 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia group (additional warming)
Number of subjects: 200
Study 8606715 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia group (routine intraoperative thermal care)
Number of subjects: 200
Study 1573344 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (nonpractitioner‐assisted) movement of the head to end range
Number of subjects: 0
Study 1573344 — intervention group
Group type: COMPARATOR
Intervention: Passive (practitioner‐assisted) movement of the head to end range
Number of subjects: 0
Study 3881086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 0
Study 30357610 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin eyedrops (2.5 mL/25 mg)
Number of subjects: 42
Study 30273332 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated whole cell pneumococcal vaccine
Number of subjects: 0
Study 30273332 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26259517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 127
Study 25012429 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg daily for 12 weeks
Number of subjects: 45
Study 21603867 — intervention group
Group type: EXPERIMENTAL
Intervention: THERACURMIN 150 mg
Number of subjects: 6
Study 21603867 — intervention group
Group type: EXPERIMENTAL
Intervention: THERACURMIN 210 mg
Number of subjects: 6
Study 21603867 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 6
Study 19583742 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A+OT
Number of subjects: 22
Study 19583742 — intervention group
Group type: COMPARATOR
Intervention: OT
Number of subjects: 22
Study 17507642 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training
Number of subjects: 146
Study 17507642 — intervention group
Group type: COMPARATOR
Intervention: Overground mobility training
Number of subjects: 146
Study 17507642 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Independence Measure (FIM)
Number of subjects: 146
Study 17507642 — intervention group
Group type: EXPERIMENTAL
Intervention: 50‐foot walking speed (50FW‐S)
Number of subjects: 146
Study 17507642 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐minute walking distance (6MW‐D)
Number of subjects: 146
Study 17507642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Extremity Motor Score (LEMS)
Number of subjects: 146
Study 17507642 — intervention group
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale (BBS)
Number of subjects: 146
Study 17507642 — intervention group
Group type: EXPERIMENTAL
Intervention: WISCI
Number of subjects: 146
Study 17507642 — intervention group
Group type: EXPERIMENTAL
Intervention: FIM locomotor score (LFIM)
Number of subjects: 146
Study 12583647 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 333
Study 12583647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 11059637 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 6500
Study 11059637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study 8729667 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures (various types)
Number of subjects: 149
Study 8729667 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy volunteers)
Number of subjects: 149
Study 1362888 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (4 mg three times daily for 3 weeks)
Number of subjects: 0
Study 6147077 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 6147077 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 6147077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (beta-blockers and diuretics)
Number of subjects: 0
Study 6147077 — intervention group
Group type: EXPERIMENTAL
Intervention: Low diuretic doses
Number of subjects: 0
Study 30425105 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CTLA4
Number of subjects: 80
Study 30425105 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD1
Number of subjects: 80
Study 28404841 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg daily for 6 weeks
Number of subjects: 36
Study 28404841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25666856 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless pedometer with cash incentives
Number of subjects: 800
Study 25666856 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless pedometer with donations to charity incentives
Number of subjects: 800
Study 25666856 — intervention group
Group type: COMPARATOR
Intervention: Wireless pedometer without incentives
Number of subjects: 800
Study 25666856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pedometer)
Number of subjects: 800
Study 24011740 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT)
Number of subjects: 2029
Study 24011740 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 2029
Study 21383276 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI plus FCU
Number of subjects: 125
Study 21383276 — intervention group
Group type: COMPARATOR
Intervention: IMI only
Number of subjects: 125
Study 19289623 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d) plus best supportive care (BSC)
Number of subjects: 201
Study 19289623 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 201
Study 19289623 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d) plus best supportive care (BSC) in EGFR FISH-positive patients
Number of subjects: 201
Study 19289623 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC) in EGFR FISH-positive patients
Number of subjects: 201
Study 17239712 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 20536
Study 17239712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20536
Study 17239712 — intervention group
Group type: EXPERIMENTAL
Intervention: N-BNP levels
Number of subjects: 20536
Study 15059444 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV) in supine position
Number of subjects: 43
Study 15059444 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (MV) in semi-reclining position
Number of subjects: 43
Study 15059444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-gastric colonization
Number of subjects: 43
Study 15059444 — intervention group
Group type: EXPERIMENTAL
Intervention: sIgA content in BALF in VAP patients
Number of subjects: 43
Study 11168029 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral azithromycin, 500 mg (n = 362)
Number of subjects: 1108
Study 11168029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 MU benzathine penicillin G, intramuscularly once (n = 374)
Number of subjects: 1108
Study 11168029 — intervention group
Group type: COMPARATOR
Intervention: No chemoprophylaxis (n = 372)
Number of subjects: 1108
Study 9132031 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic tru-cut technique
Number of subjects: 143
Study 9132031 — intervention group
Group type: COMPARATOR
Intervention: Menghini needle
Number of subjects: 143
Study 1454357 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 129
Study 1454357 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo‐ and/or radiotherapy
Number of subjects: 129
Study 1454357 — intervention group
Group type: EXPERIMENTAL
Intervention: VPB and X‐ray treatment
Number of subjects: 129
Study 1454357 — intervention group
Group type: EXPERIMENTAL
Intervention: Second line combined treatment modalities
Number of subjects: 129
Study 6201211 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation regimen A: continuous infusion of 5-azacytidine, 150 mg/sq m/day for 5 days
Number of subjects: 508
Study 6201211 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation regimen B: 5-azacytidine plus beta-deoxythioguanosine, 300 mg/sq m/day for 5 days
Number of subjects: 508
Study 6201211 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation regimen C: cytosine arabinoside, 100 mg/sq m/day intravenously, thioguanine, 100 mg/sq m orally every 12 hr, plus daunorubicin, 10 mg/sq m every 24 hr daily for 5 days
Number of subjects: 508
Study 6201211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance regimen D: chemotherapy, 5-day infusion of cytosine arabinoside and 2 days of daunorubicin (same doses as induction) given every 13 wk for 1 yr
Number of subjects: 508
Study 6201211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance regimen E: BCG given twice weekly for 1 mo and then monthly for 1 yr
Number of subjects: 508
Study 6201211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance regimen F: combination of regimens D and E
Number of subjects: 508
Study 6201211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance regimen D
Number of subjects: 508
Study 6201211 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy (not specified)
Number of subjects: 508
Study 29373113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1MHz Continuous Ultrasound (CUT; 0.4W/cm2SATA)
Number of subjects: 30
Study 29373113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1MHz Pulsed Ultrasound (PUT; 20% duty cycle, 0.08W/cm2SATA)
Number of subjects: 30
Study 29373113 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MHz Continuous Ultrasound (CUT; 0.4W/cm2SATA)
Number of subjects: 30
Study 29373113 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MHz Pulsed Ultrasound (PUT; 20% duty cycle, 0.08W/cm2SATA)
Number of subjects: 30
Study 29373113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equipment off)
Number of subjects: 30
Study 27590460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2‐1.5 μg/kg/h)
Number of subjects: 61
Study 24617350 — intervention group
Group type: EXPERIMENTAL
Intervention: Go Sun Smart program (dissemination strategy-enhanced)
Number of subjects: 0
Study 24617350 — intervention group
Group type: COMPARATOR
Intervention: Go Sun Smart program (basic dissemination strategy)
Number of subjects: 0
Study 24617350 — intervention group
Group type: EXPERIMENTAL
Intervention: High message exposure (at least 6 Go Sun Smart materials in guest-only areas and 9 materials throughout the area)
Number of subjects: 0
Study 24617350 — intervention group
Group type: COMPARATOR
Intervention: Low message exposure
Number of subjects: 0
Study 22148972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal combination of cisplatin and OK‐432 with hyperthermotherapy (Group A)
Number of subjects: 358
Study 22148972 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal combination of cisplatin and OK‐432 without hyperthermotherapy (Group B)
Number of subjects: 358
Study 22148972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 358
Study 22148972 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 358
Study 22148972 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 358
Study 20686900 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration + Exercise (VX)
Number of subjects: 20
Study 20686900 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (X)
Number of subjects: 20
Study 20686900 — intervention group
Group type: COMPARATOR
Intervention: Vibration (V)
Number of subjects: 20
Study 18235115 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg/d) in mild liver dysfunction group
Number of subjects: 89
Study 18235115 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (300 mg/d) in moderate and severe liver dysfunction groups
Number of subjects: 89
Study 18235115 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (various doses) across all liver dysfunction groups
Number of subjects: 89
Study 18235115 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (500 mg/d) in mild liver dysfunction group
Number of subjects: 89
Study 18235115 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (not specified) in moderate and severe liver dysfunction groups
Number of subjects: 89
Study 16038686 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg total dose group (four-100 microg injections over eight weeks)
Number of subjects: 18
Study 16038686 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 microg total dose group (five-400 microg vaccinations over twelve weeks)
Number of subjects: 18
Study 12521655 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (30 microg ethynyl estradiol and 150 microg levonorgestrel)
Number of subjects: 41
Study 12521655 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal contraceptive or none (control group)
Number of subjects: 41
Study 10910478 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 1490
Study 10910478 — intervention group
Group type: COMPARATOR
Intervention: Propofol plus N2O
Number of subjects: 1490
Study 9279980 — intervention group
Group type: COMPARATOR
Intervention: PROG alone (200 mg PROG twice a day for 3 days)
Number of subjects: 16
Study 9279980 — intervention group
Group type: EXPERIMENTAL
Intervention: PROG and ATQ (200 mg PROG and 500 mg ATQ twice a day for 3 days)
Number of subjects: 16
Study 1998791 — intervention group
Group type: EXPERIMENTAL
Intervention: Alutard SQ (grass pollen extract)
Number of subjects: 40
Study 1998791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30948286 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychological intervention with five sessions incorporating behavioural strategies facilitated by non-specialists
Number of subjects: 612
Study 30948286 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 612
Study 28092065 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg preoperatively followed by five 200 mg doses every 12 hours)
Number of subjects: 32
Study 28092065 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 32
Study 28092065 — intervention group
Group type: COMPARATOR
Intervention: Control (no anti-inflammatory agents)
Number of subjects: 32
Study 25812826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Adolescents (PE-A)
Number of subjects: 61
Study 25812826 — intervention group
Group type: COMPARATOR
Intervention: Client-Centered Therapy (CCT)
Number of subjects: 61
Study 23103551 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine treatment (up to 3 mg/24 h after an 8-week titration phase)
Number of subjects: 185
Study 21429448 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 26
Study 21429448 — intervention group
Group type: COMPARATOR
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 26
Study 19669675 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief simulation of auditory hallucinations (listening condition 1: sitting in a research lab)
Number of subjects: 127
Study 19669675 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief simulation of auditory hallucinations (listening condition 2: ambulating around a college campus)
Number of subjects: 127
Study 17696615 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stent implantation (n=51)
Number of subjects: 104
Study 17696615 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty with optional stenting (n=53)
Number of subjects: 104
Study 17696615 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented patients (n=68)
Number of subjects: 104
Study 17696615 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (n=36)
Number of subjects: 104
Study 16400895 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 6 weeks
Number of subjects: 1992
Study 12515103 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg)
Number of subjects: 185
Study 12515103 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (60 mg)
Number of subjects: 185
Study 9704814 — intervention group
Group type: EXPERIMENTAL
Intervention: Mircette/placebo (150 microg desogestrel and 20 microg ethinyl estradiol for 21 days followed by placebo for 7 days)
Number of subjects: 47
Study 9704814 — intervention group
Group type: COMPARATOR
Intervention: Mircette/ethinyl estradiol (150 microg desogestrel and 20 microg ethinyl estradiol for 21 days followed by 2 days placebo and 10 microg ethinyl estradiol for 5 days)
Number of subjects: 47
Study 7897460 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery
Number of subjects: 105
Study 7897460 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study 2650729 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml (75 mg) bupivacaine
Number of subjects: 30
Study 2650729 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml (112.5 mg) bupivacaine
Number of subjects: 30
Study 334218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 90
Study 334218 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 90
Study 334218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31089425 — intervention group
Group type: EXPERIMENTAL
Intervention: VIG (70% VO2peak‐reserve)
Number of subjects: 130
Study 31089425 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD (50% VO2peak‐reserve)
Number of subjects: 130
Study 31089425 — intervention group
Group type: EXPERIMENTAL
Intervention: BIKE
Number of subjects: 130
Study 31089425 — intervention group
Group type: COMPARATOR
Intervention: CON (habitual lifestyle)
Number of subjects: 130
Study 28654361 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial attention training using a computerized mobile training application for 5 hours over 2 weeks
Number of subjects: 0
Study 28654361 — intervention group
Group type: COMPARATOR
Intervention: Active placebo computerized training (control group)
Number of subjects: 0
Study 24711165 — intervention group
Group type: EXPERIMENTAL
Intervention: SpinoMed®
Number of subjects: 51
Study 24711165 — intervention group
Group type: COMPARATOR
Intervention: Soft lumbar orthosis (control group)
Number of subjects: 51
Study 22948416 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus diet therapy
Number of subjects: 334
Study 22948416 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy alone
Number of subjects: 334
Study 21223542 — intervention group
Group type: EXPERIMENTAL
Intervention: Neramexane 50 mg/day
Number of subjects: 431
Study 21223542 — intervention group
Group type: EXPERIMENTAL
Intervention: Neramexane 75 mg/day
Number of subjects: 431
Study 21223542 — intervention group
Group type: EXPERIMENTAL
Intervention: Neramexane 25 mg/day
Number of subjects: 431